Clinical Trials - February 20, 2017
AZ announces safety efficacy and safety data for durvalumab
AstraZeneca and its global biologics research and development arm, MedImmune, has announced updated efficacy and safety data for durvalumab in patients with locally-advanced or metastatic urothelial cancer (UC). Updated results from the Phase I/II trial, presented at the 2017 ASCO Genitourinary Cancers Symposium, showed an objective response rate (ORR) of 20.4% in all evaluable patients […]
Drug Development Pharma - February 17, 2017
AZ’s Siliq approved by the FDA
AstraZeneca’s partner Valeant Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved Siliq (brodalumab) injection for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. Siliq is an IL-17 receptor […]
Collaboration - February 8, 2017
Two new Swedish industry research centres with life science focus
The Swedish Foundation for Strategic Research (SSF) is investing 400 million SEK in four industrial research centres, and two of these are focusing on challenges within life science; nucleotide based drugs and personalized diabetes medicine. SSF has decided to establish four industry research centres with the purpose to enable groundbreaking innovation coming from external industrial challenges. […]
Pharma Business - January 26, 2017
Symbicort granted paediatric exclusivity in the US
AstraZeneca announces that on 25 January 2017 the US Food and Drug Administration (FDA) granted six months of paediatric exclusivity for Symbicort (budesonide/formoterol) Inhalation Aerosol. The FDA’s decision was based on the evaluation of trials conducted in children with asthma aged six up to 12 years in response to a Written Request (a prerequisite for […]
Logistics - January 18, 2017
Reaching out
Two global life science firms share some of their projects and logistical solutions to deliver healthcare to parts of the world where it is needed the most. Cardiovascular disease is currently the third leading killer in Africa. Hypertension, one of the main risk factors for cardiovascular disease, is estimated to affect nearly half of adults […]
Clinical Trials - January 17, 2017
AstraZeneca expands 1st-line immuno-oncology programme
AstraZeneca provides an update on its Immuno-Oncology (IO) late-stage clinical development programme in 1st-line non-small cell lung cancer (NSCLC), including a refinement of the Phase III MYSTIC trial. The MYSTIC trial was initially designed to assess the benefit of durvalumab monotherapy and durvalumab and tremelimumab (durva + treme) combination therapy versus standard-of-care (SoC) chemotherapy, focused […]
